BioBlast Pharma (ORPN) Posts Q2 Loss of 26c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Roth Capital Positive on BioBlast Pharma (ORPN) Following Q2 Report; H215 Should be Busy with Phase 3 Initiations
August 21, 2015 10:32 AM EDTRoth Capital affirms BioBlast Pharma (Nasdaq: ORPN) at Buy with a price target of $25 following Q2 results issued earlier Friday.
Ahead of the opening bell, BioBlast Pharma reported Q2 loss of $0.26 per share, which was $0.02 better than the analyst estimate of... More
